通过z分数对标非劣效性设计和分析。

IF 2.7 3区 医学 Q3 PHARMACOLOGY & PHARMACY
Jin Wang
{"title":"通过z分数对标非劣效性设计和分析。","authors":"Jin Wang","doi":"10.1007/s00228-025-03877-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Non-inferiority (NI) design and analyses are frequently employed to provide alternative therapy options to patients, ensuring these therapies are not significantly worse in terms of safety and effectiveness compared to the standard therapy. However, unlike superiority analysis, non-inferiority analysis faces the inherent challenge of a potentially irrelevant NI margin. It is not uncommon for the observed control performance to differ significantly from the assumed one, which can render the NI margin irrelevant. The purpose of this paper is to utilize Z-score to investigate this issue.</p><p><strong>Methods: </strong>This paper proposes using the Z-score to evaluate the NI design and connect the NI design and analysis. This approach provides a benchmark tool that even when actual outcomes differ significantly from assumptions, the NI margin can be moderated to balance clinical relevance and statistical practicality.</p><p><strong>Results: </strong>Illustrative calibrations and case studies demonstrate the feasibility of this approach, facilitating the transition from NI design to analysis.</p><p><strong>Conclusion: </strong>The Z-score can be used to assess the quality of the NI design and serve as a bridge between NI design and analysis.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1421-1427"},"PeriodicalIF":2.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Benchmarking non-inferiority design and analysis through the Z-score.\",\"authors\":\"Jin Wang\",\"doi\":\"10.1007/s00228-025-03877-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Non-inferiority (NI) design and analyses are frequently employed to provide alternative therapy options to patients, ensuring these therapies are not significantly worse in terms of safety and effectiveness compared to the standard therapy. However, unlike superiority analysis, non-inferiority analysis faces the inherent challenge of a potentially irrelevant NI margin. It is not uncommon for the observed control performance to differ significantly from the assumed one, which can render the NI margin irrelevant. The purpose of this paper is to utilize Z-score to investigate this issue.</p><p><strong>Methods: </strong>This paper proposes using the Z-score to evaluate the NI design and connect the NI design and analysis. This approach provides a benchmark tool that even when actual outcomes differ significantly from assumptions, the NI margin can be moderated to balance clinical relevance and statistical practicality.</p><p><strong>Results: </strong>Illustrative calibrations and case studies demonstrate the feasibility of this approach, facilitating the transition from NI design to analysis.</p><p><strong>Conclusion: </strong>The Z-score can be used to assess the quality of the NI design and serve as a bridge between NI design and analysis.</p>\",\"PeriodicalId\":11857,\"journal\":{\"name\":\"European Journal of Clinical Pharmacology\",\"volume\":\" \",\"pages\":\"1421-1427\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Clinical Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00228-025-03877-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00228-025-03877-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:非劣效性(NI)设计和分析经常用于为患者提供替代治疗方案,确保这些治疗在安全性和有效性方面与标准治疗相比不会明显差。然而,与优势分析不同,非劣效分析面临着潜在不相关的NI裕度的固有挑战。观察到的控制性能与假设的显著不同并不罕见,这可以使NI裕度无关。本文的目的是利用Z-score来研究这个问题。方法:本文提出用z分数来评价NI设计,并将NI设计与分析联系起来。该方法提供了一个基准工具,即使实际结果与假设有显著差异,也可以调节NI裕度以平衡临床相关性和统计实用性。结果:说明性校准和案例研究证明了这种方法的可行性,促进了从NI设计到分析的过渡。结论:Z-score可用于评估NI设计的质量,并可作为NI设计与分析之间的桥梁。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Benchmarking non-inferiority design and analysis through the Z-score.

Purpose: Non-inferiority (NI) design and analyses are frequently employed to provide alternative therapy options to patients, ensuring these therapies are not significantly worse in terms of safety and effectiveness compared to the standard therapy. However, unlike superiority analysis, non-inferiority analysis faces the inherent challenge of a potentially irrelevant NI margin. It is not uncommon for the observed control performance to differ significantly from the assumed one, which can render the NI margin irrelevant. The purpose of this paper is to utilize Z-score to investigate this issue.

Methods: This paper proposes using the Z-score to evaluate the NI design and connect the NI design and analysis. This approach provides a benchmark tool that even when actual outcomes differ significantly from assumptions, the NI margin can be moderated to balance clinical relevance and statistical practicality.

Results: Illustrative calibrations and case studies demonstrate the feasibility of this approach, facilitating the transition from NI design to analysis.

Conclusion: The Z-score can be used to assess the quality of the NI design and serve as a bridge between NI design and analysis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.40
自引率
3.40%
发文量
170
审稿时长
3-8 weeks
期刊介绍: The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed. Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor. Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves -a compound that is interesting and new in some basic or fundamental way, or -methods that are original in some basic sense, or -a highly unexpected outcome, or -conclusions that are scientifically novel in some basic or fundamental sense.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信